Cargando…

Characteristics of the Compassionate Use Program in Japan: An Analysis of Expanded Access Clinical Trials from 2016 to 2021

Compassionate use is a system that provides patients with exceptional access to investigational new drugs to treat life‐threatening diseases that have no effective conventional treatments. The purpose of this study was to characterize and assess the current status of the compassionate use program’s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maeda, Hideki, Uchida, Marika, Kusano, Mikiko, Tsukamoto, Katsura, Yamanoi, Moeka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540178/ https://www.ncbi.nlm.nih.gov/pubmed/35569010 http://dx.doi.org/10.1002/cpt.2641

Ejemplares similares

Characterizing expanded access and compassionate use programs for experimental drugs
por: Miller, Jennifer E., et al.
Publicado: (2017)

Slum compassionate community: expanding access to palliative care in Brazil
por: Mesquita, Maria Gefé da Rosa, et al.
Publicado: (2023)

Availability of Investigational Medicines Through the US Food and Drug Administration’s Expanded Access and Compassionate Use Programs
por: Puthumana, Jeremy, et al.
Publicado: (2018)

Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic.
por: Rizk, John G., et al.
Publicado: (2021)

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain
por: de la Rubia, Javier, et al.
Publicado: (2023)

Applying real-world data from expanded-access (“compassionate use”) patients to drug development
por: Wasser, June S., et al.
Publicado: (2023)

Interdependent = Compassionate? Compassionate and Self-Image Goals and Their Relationships With Interdependence in the United States and Japan
por: Niiya, Yu, et al.
Publicado: (2019)

Assessment of Drugs Approved by Public Knowledge‐Based Applications (Kouchi‐shinsei) During the Last Two Decades in Japan
por: Maeda, Hideki, et al.
Publicado: (2021)

The BC Cancer Agency Compassionate Access Program: outcome analysis of patients with esophagogastric cancer
por: Wilson, K.S., et al.
Publicado: (2009)

Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA Registry
por: Malik, Zafar, et al.
Publicado: (2020)

Compassionate Coverage: A Patient Access Linen System
por: Rabin, Jill Maura, et al.
Publicado: (2018)

An approach to data collection in compassionate use/managed access
por: Sarp, Séverine, et al.
Publicado: (2022)

Compassionate use programs in Italy: ethical guidelines
por: De Panfilis, Ludovica, et al.
Publicado: (2018)

The compassionate communities connectors program: effect on healthcare usage
por: Aoun, Samar M., et al.
Publicado: (2023)

The first successful expanded compassionate use of Iptacopan in a patient with paroxysmal nocturnal hemoglobinuria
por: Han, Bing, et al.
Publicado: (2022)

Compassionate Counterterrorism
por: Olaimy, Leena
Publicado: (2019)

Compassionate Care
por: Post, Stephen G., et al.
Publicado: (2012)

Compassionate Conversations
por: Gardner, Sharryn, et al.
Publicado: (2014)

Compassionate use of drugs and medical devices in the United States, the European Union and Japan
por: Tsuyuki, Kenichiro, et al.
Publicado: (2016)

Building Compassionate Experience Through Compassionate Action: Qualitative Behavioral Analysis
por: Desveaux, Laura, et al.
Publicado: (2023)

The teachings of the compassionate Buddha
Publicado: (1955)

The Compassionate and Forgiving Organization
por: Lennick, Doug
Publicado: (2010)

Compassionate ethics for clinics
por: Kim, Tae-Il
Publicado: (2013)

Compassionate Health Care
por: Malliarou, Maria
Publicado: (2022)

Measuring compassionate healthcare with the 12-item Schwartz Center Compassionate Care Scale
por: Rodriguez, Ana Maria, et al.
Publicado: (2019)

Microsoft Access 2016 programming pocket primer
por: Korol, Julitta
Publicado: (2016)

An analysis of common ethical justifications for compassionate use programs for experimental drugs
por: Raus, Kasper
Publicado: (2016)

Stem Cell Therapy: A Compassionate Use Program in Perianal Fistula
por: Herreros, M. D., et al.
Publicado: (2019)

Expanding the 3 Wishes Project for compassionate end-of-life care: a qualitative evaluation of local adaptations
por: Vanstone, Meredith, et al.
Publicado: (2020)

Cannabidiol and refractory epilepsy: parental and caregiver perspectives of participation in a compassionate access scheme
por: Harte, S., et al.
Publicado: (2022)

Efficacy and Safety Results of the Afatinib Expanded Access Program
por: Kim, Edward S., et al.
Publicado: (2017)

Catalog of 525 sprites observed over Japan from September 2016 to March 2021
por: Duan, Maomao, et al.
Publicado: (2023)

Implementation Models of Compassionate Communities and Compassionate Cities at the End of Life: A Systematic Review
por: Librada-Flores, Silvia, et al.
Publicado: (2020)

Correction: Measuring compassionate healthcare with the 12-item Schwartz Center Compassionate Care Scale
por: Rodriguez, Ana Maria, et al.
Publicado: (2019)

The measurement of compassionate leadership: Adaptation and Spanish validation of the compassionate leadership self‐reported scale
por: Sansó, Noemí, et al.
Publicado: (2022)

CAS Common Chemistry in 2021: Expanding Access to Trusted Chemical Information for the Scientific Community
por: Jacobs, Andrea, et al.
Publicado: (2022)

Compassionate use of cell products
por: de Santis, Gil Cunha, et al.
Publicado: (2013)

Compassionate use of orphan drugs
por: Hyry, Hanna I., et al.
Publicado: (2015)

Ethics review in compassionate use
por: Borysowski, Jan, et al.
Publicado: (2017)

COVID: Its compassionate use
por: Bennett, Jasmiry
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bdhho8uc22o19h1b55v7mgs7gh